Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 10, 2015, Pages 423-444

  Manna, Prasenjit ^a   Jain, Sushil K ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; LIPID; REACTIVE OXYGEN METABOLITE;

ADIPOSE TISSUE; ASTHMA; CHRONIC INFLAMMATION; COMORBIDITY; DIETARY INTAKE; EATING DISORDER; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; EXERCISE; HEALTH HAZARD; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERLEPTINEMIA; INFERTILITY; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MINERAL DEFICIENCY; MUSCLE CONTRACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SLEEP DISORDER; SOCIOECONOMICS; VITAMIN DEFICIENCY; WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; CALORIC RESTRICTION; DIET; ENERGY METABOLISM; METABOLISM; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; CALORIC RESTRICTION; DIET; ENERGY METABOLISM; EXERCISE; HUMANS; OBESITY; OXIDATIVE STRESS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84947216132     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0095     Document Type: Review

References (404)

1. Zhang ZY, Wang MW. Obesity, a health burden of a global nature. Acta Pharmacol Sin 2012;33:145-147.
2. Pollin IS, Kral BG, Shattuck T, et al. High prevalence of cardiometabolic risk factors in women considered low risk by traditional risk assessment. J Womens Health (Larchmt) 2008;17:947-953.
3. Jung RT. Obesity as a disease. Br Med Bull 1997;53:307-321.
4. Pi-Sunyer FX. Health implications of obesity. Am J Clin Nutr 1991;53:1595S-1603S.
5. Sikaris KA. The clinical biochemistry of obesity. Clin Biochem Rev 2004;25:165-181.
6. Despres JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10:497-511.
7. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011;12:3117-3132.
8. Savini I, Catani MV, Evangelista D, et al. Obesity-associated oxidative stress: Strategies finalized to improve redox state. Int J Mol Sci 2013;14:10497-10538.
9. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761.
10. Lee H, Lee YJ, Choi H, et al. Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J Biol Chem 2009;284:10601-10609.
11. Higuchi M, Dusting GJ, Peshavariya H, et al. Differentiation of human adipose-derived stem cells into fat involves reactive oxygen species and Forkhead box O1 mediated upregulation of antioxidant enzymes. Stem Cells Dev 2013;22:878-888.
12. Horvath TL, Andrews ZB, Diano S. Fuel utilization by hypothalamic neurons: Roles for ROS. Trends Endocrinol Metab 2009;20:78-87.
13. Serra D, Mera P, Malandrino MI, et al. Mitochondrial fatty acid oxidation in obesity. Antioxid Redox Signal 2013;19:269-284.
14. Beltowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol 2012;39:168-178.
15. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. The implication of obesity on total antioxidant capacity in apparently healthy men and women: The ATTICA study. Nutr Metab Cardiovasc Dis 2007;17:590-597.
16. Patel C, Ghanim H, Ravishankar S, et al. Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab 2007;92:4476-4479.
17. Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: An updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-1196.
18. Arora T, Singh S, Sharma RK. Probiotics: Interaction with gut microbiome and antiobesity potential. Nutrition 2013;29:591-596.
19. Gonzalez-Castejon M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: A review. Pharmacol Res 2011;64:438-455.
20. Pérez-Matute P, Crujeiras AB, Fernández-Galilea M, and Prieto-Hontoria P. Compounds with antioxidant capacity as potential tools against several oxidative stress related disorders: fact or artifact? In: Oxidative stress and diseases, VI Lushchak and DV Gospodaryov, eds. InTech: Rijeka, Croatia; 2012, 544-580.
21. Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012;3:CD007176.
22. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006;30:400-418.
23. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: Molecular mechanisms. Cardiovasc Diabetol 2002;1:1.
24. Beltowski J, Wojcicka G, Gorny D, et al. The effect of dietary-induced obesity on lipid peroxidation, antioxidant enzymes and total plasma antioxidant capacity. J Physiol Pharmacol 2000;51:883-896.
25. Ortega RM, Rodriguez-Rodriguez E, Aparicio A, et al. Young children with excess of weight show an impaired selenium status. Int J Vitam Nutr Res 2012;82:121-129.
26. Strauss RS. Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). National Health and Nutrition Examination Survey. J Pediatr 1999; 134:160-165.
27. Bouloumie A, Marumo T, Lafontan M, et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999;13:1231-1238.
28. Salvadori A, Fanari P, Fontana M, et al. Oxygen uptake and cardiac performance in obese and normal subjects during exercise. Respiration 1999;66:25-33.
29. Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003;20:255-268.
30. Martinez JA. Mitochondrial oxidative stress and inflammation: An slalom to obesity and insulin resistance. J Physiol Biochem 2006;62:303-306.
31. Khan NI, Naz L, Yasmeen G. Obesity: An independent risk factor for systemic oxidative stress. Pak J Pharm Sci 2006;19:62-65.
32. Olusi SO. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int J Obes Relat Metab Disord 2002;26:1159-1164.
33. Ozata M, Mergen M, Oktenli C, et al. Increased oxidative stress and hypozincemia in male obesity. Clin Biochem 2002;35:627-631.
34. Vincent HK, Morgan JW, Vincent KR. Obesity exacerbates oxidative stress levels after acute exercise. Med Sci Sports Exerc 2004;36:772-779.
35. Fenkci V, Fenkci S, Yilmazer M, et al. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-127.
36. Pennathur S, Heinecke JW. Mechanisms of oxidative stress in diabetes: Implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci 2004;9:565-574.
37. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599-622.
38. Diaz-Meco MT, Moscat J. The atypical PKCs in inflammation: NF-kappaB and beyond. Immunol Rev 2012;246:154-167.
39. Piperi C, Adamopoulos C, Dalagiorgou G, et al. Crosstalk between advanced glycation and endoplasmic reticulum stress: Emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab 2012;97:2231-2242.
40. Zhang H, Schmeisser A, Garlichs CD, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999;44:215-222.
41. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
42. Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem 2012;68:701-711.
43. Bakker SJ, IJzerman RG, Teerlink T, et al. Cytosolic triglycerides and oxidative stress in central obesity: The missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis 2000;148:17-21.
44. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C - dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49:1939-1945.
45. Russell AP, Gastaldi G, Bobbioni-Harsch E, et al. Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: A case of good vs. bad lipids? FEBS Lett 2003;551:104-106.
46. Vincent HK, Powers SK, Dirks AJ, et al. Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int J Obes Relat Metab Disord 2001;25:378-388.
47. Basu S, Riserus U, Turpeinen A, et al. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clin Sci (Lond) 2000;99:511-516.
48. Schleicher RL, Carroll MD, Ford ES, et al. Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr 2009;90:1252-1263.
49. Reitman A, Friedrich I, Ben-Amotz A, et al. Low plasma antioxidants and normal plasma B vitamins and homocysteine in patients with severe obesity. Isr Med Assoc J 2002;4:590-593.
50. Kaidar-Person O, Person B, Szomstein S, et al. Nutritional deficiencies in morbidly obese patients: A new form of malnutrition? Part A: Vitamins. Obes Surg 2008;18:870-876.
51. Andersen LF, Jacobs DR, Jr., Gross MD, et al. Longitudinal associations between body mass index and serum carotenoids: The CARDIA study. Br J Nutr 2006;95:358-365.
52. Kuno T, Hozumi M, Morinobu T, et al. Antioxidant vitamin levels in plasma and low density lipoprotein of obese girls. Free Radic Res 1998;28:81-86.
53. Aasheim ET, Bohmer T. Low preoperative vitamin levels in morbidly obese patients: A role of systemic inflammation? Surg Obes Relat Dis 2008;4:779-780.
54. Canoy D, Wareham N, Welch A, et al. Plasma ascorbic acid concentrations and fat distribution in 19,068 British men and women in the European Prospective Investigation into Cancer and Nutrition Norfolk cohort study. Am J Clin Nutr 2005;82:1203-1209.
55. Myara I, Alamowitch C, Michel O, et al. Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. Obes Res 2003;11:112-120.
56. Weisstaub G, Hertrampf E, Lopez de Romana D, et al. Plasma zinc concentration, body composition and physical activity in obese preschool children. Biol Trace Elem Res 2007;118:167-174.
57. Kaidar-Person O, Person B, Szomstein S, et al. Nutritional deficiencies in morbidly obese patients: A new form of malnutrition? Part B: Minerals. Obes Surg 2008;18:1028-1034.
58. Skalicky J, Muzakova V, Kandar R, et al. Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med 2008;46:499-505.
59. Cracowski JL, Bonaz B, Bessard G, et al. Increased urinary F2-isoprostanes in patients with Crohn's disease. Am J Gastroenterol 2002;97:99-103.
60. Basu S, Whiteman M, Mattey DL, et al. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann Rheum Dis 2001;60:627-631.
61. Margioris AN. Fatty acids and postprandial inflammation. Curr Opin Clin Nutr Metab Care 2009;12:129-137.
62. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783.
63. Shen HM, Pervaiz S. TNF receptor superfamily-induced cell death: Redox-dependent execution. FASEB J 2006;20:1589-1598.
64. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
65. German AJ, Ryan VH, German AC, et al. Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. Vet J 2010;185:4-9.
66. Milagro FI, Campion J, Martinez JA. Weight gain induced by high-fat feeding involves increased liver oxidative stress. Obesity (Silver Spring) 2006;14:1118-1123.
67. Fortuno A, Bidegain J, Baltanas A, et al. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. J Hypertens 2010;28:1944-1950.
68. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: The possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003;170:21-29.
69. Parola M, Marra F. Adipokines and redox signaling: Impact on fatty liver disease. Antioxid Redox Signal 2011;15:461-483.
70. Maingrette F, Renier G. Leptin increases lipoprotein lipase secretion by macrophages: Involvement of oxidative stress and protein kinase C. Diabetes 2003;52:2121-2128.
71. Saiki S, Sato T, Kohzuki M, et al. Changes in serum hypoxanthine levels by exercise in obese subjects. Metabolism 2001;50:627-630.
72. Ji LL. Exercise, oxidative stress, and antioxidants. Am J Sports Med 1996;24:S20-S24.
73. Vincent HK, Vincent KR, Bourguignon C, et al. Obesity and postexercise oxidative stress in older women. Med Sci Sports Exerc 2005;37:213-219.
74. Wolin MS, Ahmad M, Gupte SA. The sources of oxidative stress in the vessel wall. Kidney Int 2005;67:1659-1661.
75. Konior A, Schramm A, Czesnikiewicz-Guzik M, et al. NADPH oxidases in vascular pathology. Antioxid Redox Signal 2014;20:2794-2814.
76. Kaminski KA, Bonda TA, Korecki J, et al. Oxidative stress and neutrophil activation - the two keystones of ischemia/reperfusion injury. Int J Cardiol 2002;86:41-59.
77. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000;87:840-844.
78. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
79. Egan BM, Greene EL, Goodfriend TL. Insulin resistance and cardiovascular disease. Am J Hypertens 2001;14:116S-125S.
80. Schiffrin EL. Beyond blood pressure: The endothelium and atherosclerosis progression. Am J Hypertens 2002;15:115S-122S.
81. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-4501.
82. Frisbee JC, Maier KG, Stepp DW. Oxidant stress-induced increase in myogenic activation of skeletal muscle resistance arteries in obese Zucker rats. Am J Physiol Heart Circ Physiol 2002;283:H2160-H2168.
83. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:446-452.
84. Bogacka I, Xie H, Bray GA, et al. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005;54:1392-1399.
85. Koh EH, Park JY, Park HS, et al. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 2007;56:2973-2981.
86. Gao CL, Zhu C, Zhao YP, et al. Mitochondrial dysfunction is induced by high levels of glucose and free fatty acids in 3T3-L1 adipocytes. Mol Cell Endocrinol 2010;320:25-33.
87. Sutherland LN, Capozzi LC, Turchinsky NJ, et al. Time course of high-fat diet-induced reductions in adipose tissue mitochondrial proteins: Potential mechanisms and the relationship to glucose intolerance. Am J Physiol Endocrinol Metab 2008;295:E1076-E1083.
88. Vincent HK, Bourguignon CM, Taylor AG. Relationship of the dietary phytochemical index to weight gain, oxidative stress and inflammation in overweight young adults. J Hum Nutr Diet 2010;23:20-29.
89. Wallstrom P, Wirfalt E, Lahmann PH, et al. Serum concentrations of beta-carotene and alpha-tocopherol are associated with diet, smoking, and general and central adiposity. Am J Clin Nutr 2001;73:777-785.
90. Decsi T, Molnar D, Koletzko B. Reduced plasma concentrations of alpha-tocopherol and beta-carotene in obese boys. J Pediatr 1997;130:653-655.
91. Golay A, Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2005;19:649-663.
92. Hussain A, Hydrie MZI, Claussen B, Asghar S. Type 2 Diabetes and obesity: A review. J Diabetol 2010;2:1-7.
93. Kalra S. Diabesity. J Pak Med Assoc 2013;63:532-534.
94. Schienkiewitz A, Schulze MB, Hoffmann K, et al. Body mass index history and risk of type 2 diabetes: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2006;84:427-433.
95. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-969.
96. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-513.
97. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 2009;9:88.
98. Weiss R. Fat distribution and storage: How much, where, and how? Eur J Endocrinol 2007;157 Suppl 1:S39-S45.
99. National Institutes of Health. The practical guide: Identification, evaluation, and treatent of overweight and obesity in adults. Bethesda, MD: National Institute of Health; 2000, NIH Publication Number 00-4084.
100. Bjorntorp P. Abdominal fat distribution and disease: An overview of epidemiological data. Ann Med 1992;24:15-18.
101. Wei M, Gaskill SP, Haffner SM, et al. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans - a 7-year prospective study. Obes Res 1997;5:16-23.
102. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
103. Tiedge M, Lortz S, Drinkgern J, et al. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997;46:1733-1742.
104. Tanaka Y, Tran PO, Harmon J, et al. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc Natl Acad Sci U S A 2002;99:12363-12368.
105. Gurgul E, Lortz S, Tiedge M, et al. Mitochondrial catalase overexpression protects insulin-producing cells against toxicity of reactive oxygen species and proinflammatory cytokines. Diabetes 2004;53:2271-2280.
106. Hou N, Torii S, Saito N, et al. Reactive oxygen species-mediated pancreatic beta-cell death is regulated by interactions between stress-activated protein kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated protein kinase phosphatases. Endocrinology 2008;149:1654-1665.
107. Harmon JS, Stein R, Robertson RP. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J Biol Chem 2005;280:11107-11113.
108. Olson LK, Sharma A, Peshavaria M, et al. Reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to a supraphysiologic glucose concentration is associated with loss of STF-1 transcription factor expression. Proc Natl Acad Sci U S A 1995;92:9127-9131.
109. Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002;415:96-99.
110. Zhang CY, Baffy G, Perret P, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001;105:745-755.
111. Krauss S, Zhang CY, Scorrano L, et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 2003;112:1831-1842.
112. Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 2004;10:65-71.
113. Zick Y. Ser/Thr phosphorylation of IRS proteins: A molecular basis for insulin resistance. Sci STKE 2005;2005:pe4.
114. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336.
115. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275:90-94.
116. Imoto K, Kukidome D, Nishikawa T, et al. Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling. Diabetes 2006;55:1197-1204.
117. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009;119:573-581.
118. Bonnard C, Durand A, Peyrol S, et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest 2008;118:789-800.
119. Finck BN, Bernal-Mizrachi C, Han DH, et al. A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 2005;1:133-144.
120. Pospisilik JA, Knauf C, Joza N, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 2007;131:476-491.
121. Kim JJ, Li P, Huntley J, et al. FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. Diabetes 2009;58:1275-1282.
122. Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005;2:153-163.
123. Nakae J, Biggs WH, 3rd, Kitamura T, et al. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002;32:245-253.
124. Dansen TB, Smits LM, van Triest MH, et al. Redoxsensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity. Nat Chem Biol 2009;5:664-672.
125. van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007;8:440-450.
126. Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002;4:448-453.
127. Chrostowska M, Szyndler A, Hoffmann M, et al. Impact of obesity on cardiovascular health. Best Pract Res Clin Endocrinol Metab 2013;27:147-156.
128. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-1932.
129. Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995;141:1117-1127.
130. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995;333:677-685.
131. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: Effects of short- and long-term simvastatin treatment. Circulation 2002;106:1211-1218.
132. Krzystek-Korpacka M, Patryn E, Hotowy K, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: Association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med 2013;22:229-236.
133. Ferretti G, Bacchetti T, Masciangelo S, et al. HDL-paraoxonase and membrane lipid peroxidation: A comparison between healthy and obese subjects. Obesity (Silver Spring) 2010;18:1079-1084.
134. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension 2004;44:248-252.
135. Anfossi G, Russo I, Massucco P, et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: Possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004;34:482-489.
136. Merkel M, Heeren J, Dudeck W, et al. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem 2002;277:7405-7411.
137. Nishimura S, Manabe I, Nagasaki M, et al. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes 2007;56:1517-1526.
138. Gaens KH, Stehouwer CD, Schalkwijk CG. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. Curr Opin Lipidol 2013;24:4-11.
139. Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006;452:418-427.
140. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;2013:291546.
141. Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc 2008;67:128-145.
142. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta 2013;1831:1499-1508.
143. International Agency for Research on Cancer. Weight control and physical activity. In: Vainio H, Bianchini F (eds). IARC Handbook of Cancer Prevention, Vol. 6, Lyon, France: IARC Press; 2002: pp. 1-315.
144. World Cancer Research Fund. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, 2nd edition. Washington, DC: American Institute for Cancer Research; 2007.
145. Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid cancer risk among U.S. men and women: A pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011;20:464-472.
146. Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist 2010;15:1083-1101.
147. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 2002;13:540-549.
148. Crujeiras AB, Diaz-Lagares A, Carreira MC, et al. Oxidative stress associated to dysfunctional adipose tissue: A potential link between obesity, type 2 diabetes mellitus and breast cancer. Free Radic Res 2013;47:243-256.
149. Wang Y, Lam KS, Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 2007;17:280-282.
150. Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol 2005;115:897-909; quiz 910.
151. Sutherland ER. Linking obesity and asthma. Ann N Y Acad Sci 2014;1311:31-41.
152. Boulet LP. Asthma and obesity. Clin Exp Allergy 2013;43:8-21.
153. Delgado J, Barranco P, Quirce S. Obesity and asthma. J Investig Allergol Clin Immunol 2008;18:420-425.
154. Luder E, Ehrlich RI, Lou WY, et al. Body mass index and the risk of asthma in adults. Respir Med 2004;98:29-37.
155. Celedon JC, Palmer LJ, Litonjua AA, et al. Body mass index and asthma in adults in families of subjects with asthma in Anqing, China. Am J Respir Crit Care Med 2001;164:1835-1840.
156. Chen Y, Dales R, Krewski D, et al. Increased effects of smoking and obesity on asthma among female Canadians: The National Population Health Survey, 1994-1995. Am J Epidemiol 1999;150:255-262.
157. Kim S, Camargo CA, Jr. Sex-race differences in the relationship between obesity and asthma: The behavioral risk factor surveillance system, 2000. Ann Epidemiol 2003;13:666-673.
158. Nystad W, Meyer HE, Nafstad P, et al. Body mass index in relation to adult asthma among 135,000 Norwegian men and women. Am J Epidemiol 2004;160:969-976.
159. Cho YS, Moon HB. The role of oxidative stress in the pathogenesis of asthma. Allergy Asthma Immunol Res 2010;2:183-187.
160. Sahiner UM, Birben E, Erzurum S, et al. Oxidative stress in asthma. World Allergy Organ J 2011;4:151-158.
161. Ercan H, Birben E, Dizdar EA, et al. Oxidative stress and genetic and epidemiologic determinants of oxidant injury in childhood asthma. J Allergy Clin Immunol 2006;118:1097-1104.
162. Ochs-Balcom HM, Grant BJ, Muti P, et al. Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. Eur J Clin Nutr 2006;60:991-999.
163. Holguin F, Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol (1985) 2010;108:754-759.
164. Yaturu S, Davis J. Prevalence of decreased vitamin D levels is high among veterans with diabetes and/or CKD. ISRN Endocrinol 2011;2011:109458.
165. Lopez-Garcia E, Faubel R, Leon-Munoz L, et al. Sleep duration, general and abdominal obesity, and weight change among the older adult population of Spain. Am J Clin Nutr 2008;87:310-316.
166. Patel SR, Blackwell T, Redline S, et al. The association between sleep duration and obesity in older adults. Int J Obes (Lond) 2008;32:1825-1834.
167. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: Analysis of the 2002 national health interview survey data. Arch Intern Med 2006;166:1775-1782.
168. Vgontzas AN, Tan TL, Bixler EO, et al. Sleep apnea and sleep disruption in obese patients. Arch Intern Med 1994;154:1705-1711.
169. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: A population health perspective. Am J Respir Crit Care Med 2002;165:1217-1239.
170. Smith PL, Gold AR, Meyers DA, et al. Weight loss in mildly to moderately obese patients with obstructive sleep apnea. Ann Intern Med 1985;103:850-855.
171. Schwartz AR, Gold AR, Schubert N, et al. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. Am Rev Respir Dis 1991;144:494-498.
172. Lee SD, Ju G, Choi JA, et al. The association of oxidative stress with central obesity in obstructive sleep apnea. Sleep Breath 2012;16:511-517.
173. Jelic S, Lederer DJ, Adams T, et al. Vascular inflammation in obesity and sleep apnea. Circulation 2010;121:1014-1021.
174. Marchesini G, Moscatiello S, Di Domizio S, et al. Obesity-associated liver disease. J Clin Endocrinol Metab 2008;93:S74-S80.
175. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-689.
176. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.
177. Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006;103:18273-18277.
178. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
179. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004;40:1387-1395.
180. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
181. Sumida Y, Niki E, Naito Y, et al. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res 2013;47:869-880.
182. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011;412:1297-1305.
183. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59-69.
184. Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: Clinical implications and treatment. Nutr Clin Pract 2013;28:40-51.
185. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-28.
186. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: The hypertension detection and follow-up program. Am J Kidney Dis 2005;46:587-594.
187. Reynolds K, Gu D, Muntner P, et al. Body mass index and risk of ESRD in China. Am J Kidney Dis 2007;50:754-764.
188. Weisinger JR, Kempson RL, Eldridge FL, et al. The nephrotic syndrome: A complication of massive obesity. Ann Intern Med 1974;81:440-447.
189. Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis 1987;10:470-472.
190. Verani RR. Obesity-associated focal segmental glomerulosclerosis: Pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 1992;20:629-634.
191. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001;59:1498-1509.
192. Adelman RD, Restaino IG, Alon US, et al. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001;138:481-485.
193. Kao MP, Ang DS, Pall A, et al. Oxidative stress in renal dysfunction: Mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010;24:1-8.
194. Tepel M, Echelmeyer M, Orie NN, et al. Increased intracellular reactive oxygen species in patients with endstage renal failure: Effect of hemodialysis. Kidney Int 2000;58:867-872.
195. Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48:752-760.
196. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996;16:183-191.
197. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007;14:482-487.
198. Stein If LM. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.
199. Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 2002;13:184-190.
200. Norman RJ, Clark AM. Obesity and reproductive disorders: A review. Reprod Fertil Dev 1998;10:55-63.
201. Metwally M, Li TC, Ledger WL. The impact of obesity on female reproductive function. Obes Rev 2007;8:515-523.
202. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-2712.
203. Gosman GG, Katcher HI, Legro RS. Obesity and the role of gut and adipose hormones in female reproduction. Hum Reprod Update 2006;12:585-601.
204. Hammoud AO, Wilde N, Gibson M, et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008;90:2222-2225.
205. Chavarro JE, Toth TL, Wright DL, et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010;93:2222-2231.
206. Bacon CG, Mittleman MA, Kawachi I, et al. A prospective study of risk factors for erectile dysfunction. J Urol 2006;176:217-221.
207. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-463.
208. Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006;166:207-212.
209. Esposito K, Ciotola M, Giugliano F, et al. Association of body weight with sexual function in women. Int J Impot Res 2007;19:353-357.
210. Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res 2008;44:280-287.
211. Jana SK, K NB, Chattopadhyay R, et al. Upper control limit of reactive oxygen species in follicular fluid beyond which viable embryo formation is not favorable. Reprod Toxicol 2010;29:447-451.
212. Das S, Chattopadhyay R, Ghosh S, et al. Reactive oxygen species level in follicular fluid - embryo quality marker in IVF? Hum Reprod 2006;21:2403-2407.
213. Pasqualotto EB, Agarwal A, Sharma RK, et al. Effect of oxidative stress in follicular fluid on the outcome of assisted reproductive procedures. Fertil Steril 2004;81:973-976.
214. Agarwal A, Aponte-Mellado A, Premkumar BJ, et al. The effects of oxidative stress on female reproduction: A review. Reprod Biol Endocrinol 2012;10:49.
215. Du Plessis SS, Cabler S, McAlister DA, et al. The effect of obesity on sperm disorders and male infertility. Nat Rev Urol 2010;7:153-161.
216. Iwasaki A, Gagnon C. Formation of reactive oxygen species in spermatozoa of infertile patients. Fertil Steril 1992;57:409-416.
217. Zini A, de Lamirande E, Gagnon C. Reactive oxygen species in semen of infertile patients: Levels of superoxide dismutase- and catalase-like activities in seminal plasma and spermatozoa. Int J Androl 1993;16:183-188.
218. Shekarriz M, Thomas AJ, Jr., Agarwal A. Incidence and level of seminal reactive oxygen species in normal men. Urology 1995;45:103-107.
219. Tremellen K. Oxidative stress and male infertility - a clinical perspective. Hum Reprod Update 2008;14:243-258.
220. Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: A mini-review. Gerontology 2012;58:15-23.
221. Fruhbeck G, Becerril S, Sainz N, et al. BAT: A new target for human obesity? Trends Pharmacol Sci 2009;30:387-396.
222. Trayhurn P, Beattie JH. Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-339.
223. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-139.
224. Guerre-Millo M. Adipose tissue and adipokines: For better or worse. Diabetes Metab 2004;30:13-19.
225. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959-2971.
226. Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta 2013;419:87-94.
227. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
228. Ouchi N, Ohashi K, Shibata R, et al. Adipocytokines and obesity-linked disorders. Nagoya J Med Sci 2012;74:19-30.
229. Rabe K, Lehrke M, Parhofer KG, et al. Adipokines and insulin resistance. Mol Med 2008;14:741-751.
230. Zhao YF, Feng DD, Chen C. Contribution of adipocytederived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol 2006;38:804-819.
231. Dunmore SJ, Brown JE. The role of adipokines in betacell failure of type 2 diabetes. J Endocrinol 2013;216:T37-T45.
232. Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun 1996;224:522-527.
233. Kieffer TJ, Heller RS, Leech CA, et al. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 1997;46:1087-1093.
234. Kieffer TJ, Habener JF. The adipoinsular axis: Effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 2000;278:E1-E14.
235. Zhao AZ, Bornfeldt KE, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 1998;102:869-873.
236. Lee JW, Swick AG, Romsos DR. Leptin constrains phospholipase C-protein kinase C-induced insulin secretion via a phosphatidylinositol 3-kinase-dependent pathway. Exp Biol Med (Maywood) 2003;228:175-182.
237. Kulkarni RN, Wang ZL, Wang RM, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 1997;100:2729-2736.
238. Pallett AL, Morton NM, Cawthorne MA, et al. Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem Biophys Res Commun 1997;238:267-270.
239. Okuya S, Tanabe K, Tanizawa Y, et al. Leptin increases the viability of isolated rat pancreatic islets by suppressing apoptosis. Endocrinology 2001;142:4827-4830.
240. Shimabukuro M, Wang MY, Zhou YT, et al. Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A 1998;95:9558-9561.
241. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863-25866.
242. Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003;278:2461-2468.
243. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769.
244. Rakatzi I, Mueller H, Ritzeler O, et al. Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 2004;47:249-258.
245. Huypens P, Moens K, Heimberg H, et al. Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci 2005;77:1273-1282.
246. Zhang S, Kim KH. TNF-alpha inhibits glucose-induced insulin secretion in a pancreatic beta-cell line (INS-1). FEBS Lett 1995;377:237-239.
247. Tsiotra PC, Tsigos C, Raptis SA. TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord 2001;25:1018-1026.
248. Cirulli V, Halban PA, Rouiller DG. Tumor necrosis factor-alpha modifies adhesion properties of rat islet B cells. J Clin Invest 1993;91:1868-1876.
249. Stephens LA, Thomas HE, Ming L, et al. Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells. Endocrinology 1999;140:3219-3227.
250. Ishizuka N, Yagui K, Tokuyama Y, et al. Tumor necrosis factor alpha signaling pathway and apoptosis in pancreatic beta cells. Metabolism 1999;48:1485-1492.
251. Dunger A, Cunningham JM, Delaney CA, et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement. Diabetes 1996;45:183-189.
252. Rabinovitch A, Suarez-Pinzon W, Strynadka K, et al. Transfection of human pancreatic islets with an antiapoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction. Diabetes 1999;48:1223-1229.
253. Suzuki T, Imai J, Yamada T, et al. Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic betacells: Potential involvement of the PLC-IP3-dependent pathway. Diabetes 2011;60:537-547.
254. Shimizu H, Ohtani K, Kato Y, et al. Interleukin-6 increases insulin secretion and preproinsulin mRNA expression via Ca2+-dependent mechanism. J Endocrinol 2000;166:121-126.
255. Sandler S, Bendtzen K, Eizirik DL, et al. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 1990;126:1288-1294.
256. Barzilai N, Wang J, Massilon D, et al. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997;100:3105-3110.
257. Ebihara K, Ogawa Y, Masuzaki H, et al. Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 2001;50:1440-1448.
258. Appleton DJ, Rand JS, Sunvold GD. Plasma leptin concentrations are independently associated with insulin sensitivity in lean and overweight cats. J Feline Med Surg 2002;4:83-93.
259. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
260. Kahn BB, Alquier T, Carling D, et al. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
261. Morton GJ, Gelling RW, Niswender KD, et al. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab 2005;2:411-420.
262. Marti A, Berraondo B, Martinez JA. Leptin: Physiological actions. J Physiol Biochem 1999;55:43-49.
263. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770.
264. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013;2:133-141.
265. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008;93:3165-3172.
266. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
267. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
268. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614.
269. Jellema A, Plat J, Mensink RP. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 2004;34:766-773.
270. Klover PJ, Zimmers TA, Koniaris LG, et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-2789.
271. Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-3399.
272. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-45784.
273. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
274. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-E751.
275. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-945.
276. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: The macro- and microcirculation of adipose tissue. FEBS J 2009;276:5738-5746.
277. Skurk T, Alberti-Huber C, Herder C, et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92:1023-1033.
278. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: Role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807-825.
279. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356-362.
280. Goldstein BJ, Scalia R. Adipokines and vascular disease in diabetes. Curr Diab Rep 2007;7:25-33.
281. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009;6:27-35.
282. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767-2770.
283. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 2004;344:1-12.
284. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
285. Sweeney G. Cardiovascular effects of leptin. Nat Rev Cardiol 2010;7:22-29.
286. Hou N, Luo JD. Leptin and cardiovascular diseases. Clin Exp Pharmacol Physiol 2011;38:905-913.
287. Martin SS, Qasim A, Reilly MP. Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008;52:1201-1210.
288. Enriori PJ, Evans AE, Sinnayah P, et al. Leptin resistance and obesity. Obesity (Silver Spring) 2006;14 Suppl 5:254S-258S.
289. Wannamethee SG, Shaper AG, Whincup PH, et al. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: Does leptin have a role? J Am Coll Cardiol 2011;58:1870-1877.
290. Kunnari A, Ukkola O, Paivansalo M, et al. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006;91:2755-2760.
291. Norata GD, Ongari M, Garlaschelli K, et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156:279-284.
292. Lubos E, Messow CM, Schnabel R, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007;193:121-128.
293. Calabro P, Samudio I, Willerson JT, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004;110:3335-3340.
294. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006;70:146-157.
295. Dick GM, Katz PS, Farias M, 3rd, et al. Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am J Physiol Heart Circ Physiol 2006;291:H2997-H3002.
296. Milan G, Granzotto M, Scarda A, et al. Resistin and adiponectin expression in visceral fat of obese rats: Effect of weight loss. Obes Res 2002;10:1095-1103.
297. Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092-1101.
298. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
299. Redinger RN. The pathophysiology of obesity and its clinical manifestations. Gastroenterol Hepatol (N Y) 2007;3:856-863.
300. Kim S, Popkin BM. Commentary: Understanding the epidemiology of overweight and obesity - a real global public health concern. Int J Epidemiol 2006;35:60-67;discussion 81-62.
301. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-336.
302. Wang SN, Yeh YT, Yang SF, et al. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol 2006;59:930-934.
303. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006;147:4505-4516.
304. Barb D, Williams CJ, Neuwirth AK, et al. Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86:s858-s866.
305. Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: A link between obesity and cancer. Expert Opin Investig Drugs 2006;15:917-931.
306. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-1154.
307. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-643.
308. Brashier B, Salvi S. Obesity and asthma: Physiological perspective. J Allergy (Cairo) 2013;2013:198068.
309. Khan UI, Rastogi D, Isasi CR, et al. Independent and synergistic associations of asthma and obesity with systemic inflammation in adolescents. J Asthma 2012;49:1044-1050.
310. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999;54:825-857.
311. Thomas PS. Tumour necrosis factor-alpha: The role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001;79:132-140.
312. Sukkar MB, Hughes JM, Armour CL, et al. Tumour necrosis factor-alpha potentiates contraction of human bronchus in vitro. Respirology 2001;6:199-203.
313. Heijink IH, Vellenga E, Borger P, et al. Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells. Immunology 2002;107:316-324.
314. Shore SA. Obesity and asthma: Lessons from animal models. J Appl Physiol (1985) 2007;102:516-528.
315. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603-2607.
316. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004;89:2119-2126.
317. Vgontzas AN, Bixler EO, Lin HM, et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005;12:131-140.
318. Vgontzas AN, Pejovic S, Zoumakis E, et al. Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am J Physiol Endocrinol Metab 2007;292:E253-E261.
319. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-1694.
320. Vgontzas AN. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? Arch Physiol Biochem 2008;114:211-223.
321. Punjabi NM, Beamer BA. C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 2007;30:29-34.
322. Kaplan ML, Leveille GA. Obesity: Prediction of preobesity among progeny from crosses of ob+ mice. Proc Soc Exp Biol Med 1973;143:925-928.
323. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-1271.
324. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007;92:532-541.
325. Margetic S, Gazzola C, Pegg GG, et al. Leptin: A review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002;26:1407-1433.
326. Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996;348:159-161.
327. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
328. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007;13:3540-3553.
329. Louthan MV, Barve S, McClain CJ, et al. Decreased serum adiponectin: An early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005;147:835-838.
330. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746.
331. Briffa JF, McAinch AJ, Poronnik P, et al. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 2013;305:F1629-F1636.
332. Lee MP, Orlov D, Sweeney G. Leptin induces rat glomerular mesangial cell hypertrophy, but does not regulate hyperplasia or apoptosis. Int J Obes (Lond) 2005;29:1395-1401.
333. Wohlfarth V, Drumm K, Mildenberger S, et al. Protein uptake disturbs collagen homeostasis in proximal tubule-derived cells. Kidney Int Suppl 2003;S103-S109.
334. Wolf G, Schroeder R, Ziyadeh FN, et al. Albumin upregulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. Kidney Int 2004;66:1849-1858.
335. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis [seecomments]. Kidney Int 1999;56:860-872.
336. Lee MP, Madani S, Sekula D, et al. Leptin increases expression and activity of matrix metalloproteinase-2 and does not alter collagen production in rat glomerular mesangial cells. Endocr Res 2005;31:27-37.
337. Dagogo-Jack S, Ovalle F, Landt M, et al. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1998;18:34-40.
338. Merabet E, Dagogo-Jack S, Coyne DW, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997;82:847-850.
339. Doumatey AP, Zhou J, Huang H, et al. Circulating adiponectin is associated with renal function independent of age and serum lipids in west africans. Int J Nephrol 2012;2012:730920.
340. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008;118:1645-1656.
341. Decleves AE, Mathew AV, Cunard R, et al. AMPK mediates the initiation of kidney disease induced by a highfat diet. J Am Soc Nephrol 2011;22:1846-1855.
342. Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006;69:596-604.
343. Menzaghi C, Salvemini L, Fini G, et al. Serum resistin and kidney function: A family-based study in non-diabetic, untreated individuals. PLoS One 2012;7:e38414.
344. Cohen G, Horl WH. Resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin. Semin Dial 2009;22:373-377.
345. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009;41:150-153.
346. Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008;23:959-965.
347. Huang Q, Guo Y, Zeng H, et al. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res 2011;36:93-100.
348. Mitchell M, Armstrong DT, Robker RL, et al. Adipokines: Implications for female fertility and obesity. Reproduction 2005;130:583-597.
349. Chen X, Jia X, Qiao J, et al. Adipokines in reproductive function: A link between obesity and polycystic ovary syndrome. J Mol Endocrinol 2013;50:R21-R37.
350. Farooq R, Lutfullah S, Ahmed M. Serum leptin levels in obese infertile men and women. Pak J Pharm Sci 2014;27:67-71.
351. Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-3680.
352. Yildizhan R, Ilhan GA, Yildizhan B, et al. Serum retinolbinding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. Fertil Steril 2011;96:246-250.
353. Campos DB, Palin MF, Bordignon V, et al. The 'beneficial' adipokines in reproduction and fertility. Int J Obes (Lond) 2008;32:223-231.
354. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:251-282.
355. Carmina E, Orio F, Palomba S, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005;152:389-394.
356. Chabrolle C, Tosca L, Dupont J. Regulation of adiponectin and its receptors in rat ovary by human chorionic gonadotrophin treatment and potential involvement of adiponectin in granulosa cell steroidogenesis. Reproduction 2007;133:719-731.
357. Ledoux S, Campos DB, Lopes FL, et al. Adiponectin induces periovulatory changes in ovarian follicular cells. Endocrinology 2006;147:5178-5186.
358. Manna P, Sil PC. Arjunolic acid: Beneficial role in type 1 diabetes and its associated organ pathophysiology. Free Radic Res 2012;46:815-830.
359. Oh S, Tanaka K, Warabi E, et al. Exercise reduces inflammation and oxidative stress in obesity-related liver diseases. Med Sci Sports Exerc 2013;45:2214-2222.
360. Parra D, Ramel A, Bandarra N, et al. A diet rich in long chain omega-3 fatty acids modulates satiety in overweight and obese volunteers during weight loss. Appetite 2008;51:676-680.
361. Kushner RF, Doerfler B. Low-carbohydrate, high-protein diets revisited. Curr Opin Gastroenterol 2008;24:198-203.
362. Larsen TM, Dalskov S, van Baak M, et al. The Diet, Obesity and Genes (Diogenes) Dietary Study in eight European countries - a comprehensive design for longterm intervention. Obes Rev 2010;11:76-91.
363. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003;348:2082-2090.
364. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial. Ann Intern Med 2004;140:778-785.
365. Raben A, Astrup A, Vasilaras TH, et al. [The CARMEN trial: Increased intake of carbohydrates - simple or complex - and unchanged blood lipids in overweight subjects]. Ugeskr Laeger 2002;164:627-631.
366. Saris WH, Astrup A, Prentice AM, et al. Randomized controlled trial of changes in dietary carbohydrate/fat ratio and simple vs complex carbohydrates on body weight and blood lipids: The CARMEN study. The Carbohydrate Ratio Management in European National diets. Int J Obes Relat Metab Disord 2000;24:1310-1318.
367. Teegarden D, White KM, Lyle RM, et al. Calcium and dairy product modulation of lipid utilization and energy expenditure. Obesity (Silver Spring) 2008;16:1566-1572.
368. Major GC, Alarie FP, Dore J, et al. Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: Potential link with a calcium-specific appetite control. Br J Nutr 2009;101:659-663.
369. Zemel MB. The role of dairy foods in weight management. J Am Coll Nutr 2005;24:537s-546s.
370. Bendsen NT, Hother AL, Jensen SK, et al. Effect of dairy calcium on fecal fat excretion: A randomized crossover trial. Int J Obes (Lond) 2008;32:1816-1824.
371. Myers VH, Champagne CM. Nutritional effects on blood pressure. Curr Opin Lipidol 2007;18:20-24.
372. Ard JD, Grambow SC, Liu D, et al. The effect of the PREMIER interventions on insulin sensitivity. Diabetes Care 2004;27:340-347.
373. Azadbakht L, Mirmiran P, Esmaillzadeh A, et al. Beneficial effects of a dietary approaches to stop hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005;28:2823-2831.
374. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004;27:2741-2751.
375. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: Meta-analysis of randomized trials. Int J Obes Relat Metab Disord 2003;27:522-529.
376. Onakpoya I, Posadzki P, Ernst E. Chromium supplementation in overweight and obesity: A systematic review and meta-analysis of randomized clinical trials. Obes Rev 2013;14:496-507.
377. Boeing H, Bechthold A, Bub A, et al. Critical review: Vegetables and fruit in the prevention of chronic diseases. Eur J Nutr 2012;51:637-663.
378. Tetens I, Alinia S. The role of fruit consumption in the prevention of obesity. J Hortic Sci Biotechnol 2009;47-51.
379. Grunwald GK, Seagle HM, Peters JC, et al. Quantifying and separating the effects of macronutrient composition and non-macronutrients on energy density. Br J Nutr 2001;86:265-276.
380. Haber GB, Heaton KW, Murphy D, et al. Depletion and disruption of dietary fibre. Effects on satiety, plasmaglucose, and serum-insulin. Lancet 1977;2:679-682.
381. Bolton RP, Heaton KW, Burroughs LF. The role of dietary fiber in satiety, glucose, and insulin: Studies with fruit and fruit juice. Am J Clin Nutr 1981;34:211-217.
382. Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. Nutr Rev 2001;59:129-139.
383. Gustafsson K, Asp NG, Hagander B, et al. Effects of different vegetables in mixed meals on glucose homeostasis and satiety. Eur J Clin Nutr 1993;47:192-200.
384. Gustafsson K, Asp NG, Hagander B, et al. Satiety effects of spinach in mixed meals: Comparison with other vegetables. Int J Food Sci Nutr 1995;46:327-334.
385. Gustafsson K, Asp NG, Hagander B, et al. Dose-response effects of boiled carrots and effects of carrots in lactic acid in mixed meals on glycaemic response and satiety. Eur J Clin Nutr 1994;48:386-396.
386. Astrup A. Dietary management of obesity. JPEN J Parenter Enteral Nutr 2008;32:575-577.
387. Cheskin LJ, Mitchell AM, Jhaveri AD, et al. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: A controlled clinical trial. Diabetes Educ 2008;34:118-127.
388. Li Z, Hong K, Saltsman P, et al. Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: Relative effects on weight loss, metabolic parameters, and C-reactive protein. Eur J Clin Nutr 2005;59:411-418.
389. Smeets AJ, Soenen S, Luscombe-Marsh ND, et al. Energy expenditure, satiety, and plasma ghrelin, glucagon-like peptide 1, and peptide tyrosine-tyrosine concentrations following a single high-protein lunch. J Nutr 2008;138:698-702.
390. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003;4:CD004094.
391. Carter R, Mouralidarane A, Ray S, et al. Recent advancements in drug treatment of obesity. Clin Med 2012;12:456-460.
392. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007;132:2239-2252.
393. Vetter ML, Faulconbridge LF, Webb VL, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 2010;6:578-588.
394. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J Obes 2011;2011:179674.
395. Chechi K, Nedergaard J, Richard D. Brown adipose tissue as an anti-obesity tissue in humans. Obes Rev 2014;15:92-106.
396. Tam CS, Lecoultre V, Ravussin E. Brown adipose tissue: Mechanisms and potential therapeutic targets. Circulation 2012;125:2782-2791.
397. Rothwell NJ, Stock MJ. A role for brown adipose tissue in diet-induced thermogenesis. Nature 1979;281:31-35.
398. Hamann A, Benecke H, Le Marchand-Brustel Y, et al. Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes 1995;44:1266-1273.
399. Hamann A, Flier JS, Lowell BB. Decreased brown fat markedly enhances susceptibility to diet-induced obesity, diabetes, and hyperlipidemia. Endocrinology 1996;137:21-29.
400. Arch JR, Kaumann AJ. Beta 3 and atypical betaadrenoceptors. Med Res Rev 1993;13:663-729.
401. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-1525.
402. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360:1509-1517.
403. Wijers SL, Saris WH, van Marken Lichtenbelt WD. Individual thermogenic responses to mild cold and overfeeding are closely related. J Clin Endocrinol Metab 2007;92:4299-4305.
404. Lopez M, Varela L, Vazquez MJ, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010;16:1001-1008.